Emerging drugs for gastro-oesophageal reflux disease

Bibliography

• THOMPSON WG, HEATON KW:Heartburn and globus in apparently healthy people. Can. Med. Assoc. J. (1982) 126:46–48.
   PubMed Web of Science ®Google Scholar
• LOCKE GR, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ: Prevalence and clinical spectrum of gastro-oesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 112:1448–1456.
   PubMed Web of Science ®Google Scholar
• DENT J: The role of the specialist in the diagnosis and short and long term care of patients with gastroesophageal reflux disease. Am. J. GastroenteroL (2001) 96(Suppl.):S22–S26.
   Google Scholar
• MITTAL RK, BALABAN DH: Mechanisms of disease: the esophagogastric junction. N EngL j Med. (1997) 336:924–932.
   PubMed Web of Science ®Google Scholar
• LIDUMS I, LEHMAN A, CHECKLIN H et al.: Control of lower esophageal sphincter relaxations and reflux by GABAB agonist baclofen in normal subjects. Gastroenterology (2000) 118:7–13.
   PubMed Web of Science ®Google Scholar
• WYMAN JB, DENT J, DODDS WJ, TOOULI J, DOWNTON J: Control of belching by the lower oesophageal sphincter. Gut (1990) 31: 639–646.
   Google Scholar
• MARTIN CJ, PATRIKIOS J, DENT J: Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. Gastroenterology (1986) 91:890–896.
   PubMed Web of Science ®Google Scholar
• MADDERN GJ, JAMIESON GG: Oesophageal emptying in patients with gastro-oesophageal reflux. Br. J. Surg. (1986) 73:615–617.
   PubMed Web of Science ®Google Scholar
• KAHRILAS PJ, DODDS WJ, HOGAN WJ, KERN R, ARNDORFER RC, RECCE k Oesophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology (1986) 91:897–904.
   PubMed Web of Science ®Google Scholar
• IASCONE C, DEMEESTER TR, LITTLE AG, SKINNER DB: Barrett'soesophagus functional assessment, proposed pathogenesis, and surgical therapy. Arch. Surg. (1983) 118:543–549.
   PubMed Web of Science ®Google Scholar
• RICHTER JE: Importance of bile reflux inBarrett's esophagus. Dig. Dis. (2000) 18:8–16.
   Google Scholar
• TODD JA, BASU KK, DE CAESTECKER JS: Normalisation of oesophageal pH does not guarantee control of duodenogastroesophageal reflux. Alim. PharmacoL Therap (2005) (in press).
   PubMed Web of Science ®Google Scholar
• JANKOWSKI J, HARRISON RF, PERRY I, BALKWILL F, TSELEPIS C: Seminar: Barrett's metaplasia. Lancet (2000) 356:2079–2085.
   PubMed Web of Science ®Google Scholar
• SAVARY M, MILLER G: The oesophagus. In: Handbook and atlas of endoscopy. Gassman AG (Ed.), Solothorn, Switzerland (1978).
   Google Scholar
• ARMSTRONG D, MONNIER P, NICOLET M, BLUM AL, SAVARY M: Endoscopic assessment of oesophagitis. Gullet (1991) 1:63–67.
   Google Scholar
• LUNDELL LR, DENT J, BENNETT JR et al.: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 45:172–180.
   PubMed Web of Science ®Google Scholar
• DE CAESTECKER JS, BENNETT J: The role of endoscopy in gastro-oesophageal reflux disease. In: Guidelines for Management of Symptomatic Gastro-oesophageal reflux disease. Lundell L (Ed.), Science Press, London (1998):15–24.
   Google Scholar
• SVOBODA AC: Increasing concerns about chronic proton pump inhibitor use. J. Clin. GastroenteroL (2001) 33:3–7.
   PubMed Web of Science ®Google Scholar
• HARVEY RF, GORDON PC, HADLEY N et al.: Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet (1987) 2:1200–1203.
   PubMed Web of Science ®Google Scholar
• SCARPIGNATO C: Sucralfate and othermucosal protective compounds: pharmacology and potential in the treatment of esophageal lesions. Front Gastrointest. Res. (1992) 20:317–346.
   Google Scholar
• GRAHAM DY, PATTERSON DJ: Double-blind comparison of liquid antacids and placebo in the treatment of symptomatic reflux oesophagitis. Dig. Dis. Sci. (1983) 28:559–563.
   PubMed Web of Science ®Google Scholar
• WEISS W, BRUNNER H, BUTTNER G et al.: Therapie der Reflux-Osophagitis mit Sucralfat. Dtsch Med. Wochensch (1984) 108:1706–1711.
   Web of Science ®Google Scholar
• CARLING L, CRONSTEDT J, ENGQUIST A et al.: Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study. Scand. Gastroenterol. (1988) 23:1117–1124.
   PubMed Web of Science ®Google Scholar
• SCHUURKES JA, VAN NUETEN JM: Dose-dependant stimulation of antroduodenal coordination by domperidone via specific dopamine-receptors. Arch. Int. PharmacoL Ther. (1982) 256:311–314.
   PubMedGoogle Scholar
• GUSLANDI M, TESTONI PA, PASSARETTI S et al.: Ranitidine versus metoclopramide in the medical treatment of reflux oesophagitis. Hepato. GastroenteroL (1983) 30:96–98.
   PubMed Web of Science ®Google Scholar
• VALENZUELA JE: Effects of domperidone on the symptoms of reflux oesophagitis. Progress with domperidone. Royal Society of Medicine, International Congress and Symposium Series (1981) 36:51.
   Google Scholar
• ROBINSON OPW: Metoclopramide - side effects and safety. Postgrad. Med. (1973) 49(Suppl. 4):77–80.
   Google Scholar
• SCHUURKES JA, VAN NUETEN JM, VAN DAELE PG, REYNTJENS AJ, JANSSEN PAJ: Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J. Pharmacol. Exp. Ther. (1985) 234:775–783.
   PubMed Web of Science ®Google Scholar
• VAN NUETEN JM, SCHUURKES JA: Development of a gastrointestinal prokinetic: pharmacology of cisapride. In: Advances in drug therapy of gastroesophageal Expert Op/n. Emerging Drugs (2005) 10(2) reflux disease. Scarpignato C (Ed.). Front. Gastrointest. Res. (1992) 20:54–63.
   Google Scholar
• KYRMIZAKIS DE, CHIMONA TS, KANOUPAKIS EM, PAPADAKIS CE, VELEGRAKIS GA, HELIDONIS ES: QT prolongation and torsade de pointes associated with concurrent use of cisapride and erythromycin. Am. J. Otolaryng. (2002) 23:303–307.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, FAULDS D: Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs (1994) 47:116–152.
   PubMed Web of Science ®Google Scholar
• BLUM AL, ADAMI B, BOUZO MH et al.: Effect of cisapride on relapse of oesophagitis: a multinational, placebo controlled trial in patients healed with an antisecretory drug. Dig. Dis. Sci. (1993) 38:551–560.
   PubMed Web of Science ®Google Scholar
• HATLEBAKK JG, JOHNSSON F, VILIEN M, CARLING L, WETTERHUS S, THOGERSEN T: The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand. Gastroenterol. (1997) 32:1100–1106.
   PubMed Web of Science ®Google Scholar
• TYTGAT GNw, ANKER-HANSEN O, CARLING L et al.: Effect of cisapride on relapse of reflux oesophagitis, healed with antisecretory drugs. Scand. j Gastroenterol. (1992) 27:175–183.
   PubMed Web of Science ®Google Scholar
• VIGNERI S, TERMINI R, LEANDRO G et al.: A comparison of five maintenance therapies for reflux esophagitis. N Engl. J. Med. (1995) 333:1106–1110.
   PubMed Web of Science ®Google Scholar
• DE CAESTECKER JS: Prokinetics and reflux - a promise unfulfilled. Eur. Gastroenterol. Hepatol. (2001) 13:1–3.
   PubMed Web of Science ®Google Scholar
• ORR WC, ROBINSON MG, HUMPHRIES TJ, ANTONELLO J, CAGLIOLA A: Dose response effect of famotidine on patterns of gastro-esophageal reflux. Alim. PharmacoL Ther. (1988) 2:229–235.
   PubMed Web of Science ®Google Scholar
• TYTGAT GN, NICOLAI JJ, REMAN FC: Efficacy of different doses of cimetidine in the treatment of reflux oesophagitis. A review of three large double blind controlled trials. Gastroenterology (1990) 99:629–634.
   PubMed Web of Science ®Google Scholar
• CLOUD M, OFFEN W: Nizatidine 150 bid relieves symptoms and decreases severity of oesophagitis in gastro-esophageal reflux disease. Gastroenterology (1989) 96:A91.
   Google Scholar
• HALVORSEN L, LEE Fl, WESDORP IC, JOHNSON NJ, MILLS JG, WOOD JR: Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime. Aliment PharmacoL Thera)). (1989) 3:171–181.
   PubMed Web of Science ®Google Scholar
• BOVERO E, CHELI R, BARBARA L et al.: Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study. Hey) at. Gastroenterol. (1987) 34:155–159.
   Web of Science ®Google Scholar
• ROUFAIL W, BELSITO A, ROBINSON M, BARISH C, RUBIN A: Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group. Alim. Pharmacol. Ther. (1992) 6:597–607.
   PubMed Web of Science ®Google Scholar
• SIMON TJ, BERLIN RG, TIPPING R, GILDE L: Efficacy of twice daily dose of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate or severe erosive oesophagitis. Scand. J. Gastroenterol. (1993) 28:375–380.
   PubMed Web of Science ®Google Scholar
• SIMON TJ, BERENSON MM, BERLIN AG, SNAPINN S, CAGLIOLA A: Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. Alim. PharmacoL Therap. (1994) 8:71–79.
   PubMed Web of Science ®Google Scholar
• WESDORP ICE, DEKKER W, FESTEN HPM: Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux oesophagitis. Dig. Dis. Sci. (1993) 38:2287–2293.
   PubMed Web of Science ®Google Scholar
• SHERBANIUK R, WENSEL R, BAILEY R et al.: Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J. Clin. Gastroenterol. (1984) 4:9–15.
   Web of Science ®Google Scholar
• BERLIN RG, EBEL D, COOK T: International oesophagitis study group. Famotidine 20 mg hs and 40 mg hs versus placebo in maintenance therapy of reflux oesophagitis: results of a double-blind multi-centre study. Gastroenterology (1989) 96:A39.
   Google Scholar
• PIPER DW: A comparative overview of theadverse effects of antiulcer drugs. Drug Safety (1995) 12:120–138.
   PubMed Web of Science ®Google Scholar
• ANDERSSON T, CEDERBERG C, EVARDSSON G, HEGGELUND A, LUNDBORG P: Effect of omeprazole treatment on diazepam plasma concentrations in slow versus normal rapid metabolisers of omeprazole. Clin. PharmacoL Therap. (1990) 47:79–85.
   PubMed Web of Science ®Google Scholar
• HOLTMANN G, BYTZER P, BLUM AL: Clinical efficacy of a standard dose rabeprazole and a high dose omeprazole for the relief of GERD symptoms. Gastroenterology (2001) 120(Suppl. 3):62.
   Google Scholar
• KUO B, CASTELL DO: Optimal dosing of omeprazole 40 mg daily: effects on gastric acid and esophageal pH and serum gastrin in healthy controls. Am. J. Gastroenterol. (1996) 91:1532–1538.
   PubMed Web of Science ®Google Scholar
• CASTELL DO, RICHTER JE, ROBINSON M, SONTAG SJ, HABER MM: Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am. J. Gastroenterol. (1996) 91:1749–1757.
   PubMed Web of Science ®Google Scholar
• MEE AS, ROWLEY JL: Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Alim. PharmacoL Therap. (1996) 10:757–763.
   PubMed Web of Science ®Google Scholar
• FARLEY A, WRUBLE LD, HUMPHRIES TJ: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double blind randomised clinical trial. Rabeprazole Study Group. Am. J. Gastroenterol. (2000) 95:1894–1899.
   PubMed Web of Science ®Google Scholar
• DELCHIER JC, COHEN G, HUMPHRIES TJ: Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand. j Gastroenterol. (2000) 35:1245–1250.
   PubMed Web of Science ®Google Scholar
• MOESSNER J, HOELSCHER AH, HERZ R, SCHNEIDER k A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Alim. PharmacoL Ther. (1995) 9:321–326.
   PubMed Web of Science ®Google Scholar
• CASTELL DO, KAHRILAS PJ, RICHTER JE et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol. (2002) 97:575–583.
   PubMed Web of Science ®Google Scholar
• MINER P, KATZ PO, CHEN Y, SOSTEK M. Gastric acid control with esomeprazole, lanzoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. (2003) 98:2616–2620.
   PubMed Web of Science ®Google Scholar
• POYNARD T: Relapse rate of patients afterhealing of oesophagitis: a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group. Alim. PharmacoL Therap. (1993) 7:385–392.
   PubMed Web of Science ®Google Scholar
• DENT J, YEOMANS ND, MACKINNON M et al.: Omeprazole versus ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut (1994) 35:590–598.
   PubMed Web of Science ®Google Scholar
• GOUGH AL, LONG RG, COOPER BT, FOSTERS CS, GARRETT AD, LANG WORTHY CH: Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Alim. Pharmacol. Ther. (1996) 10:529–539.
   PubMed Web of Science ®Google Scholar
• JANSEN J, HAECK PWE, SNEL P et al.: What is the preferred dose of lansoprazole in the maintenance therapy of reflux oesophagitis? The results of a Dutch multi-centre comparative trial. Eur. GastroenteroL Hepatol. (1998) 10:A48–A49.
   Google Scholar
• BATE CM, BOOTH SN, CROWE JP: Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut (1995) 36: 492–498.
   Google Scholar
• CARLING L, AXELSSON C, FORSELL H et al.: Lansoprazole versus omeprazole in long-term maintenance treatment of reflux oesophagitis. A Scandinavian multicentre trial. Gut (1996) 39(Suppl. 3):182.
   Google Scholar
• BALDI F, BARDHAN KD, BORMAN BC: Lansoprazole maintains healing in patients with reflux oesophagitis. Gastroenterology (1996) 110(Suppl.):55.
   Google Scholar
• ESCOURROU J, DEPREZ P, SAGGIORO A. GELDOF H, FISCHER R, MATER C: Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Alim. Pharmacol. Therap. (1999) 13:1481–1491.
   PubMed Web of Science ®Google Scholar
• FASS R, OFMAN JJ, GRALNEK IM et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Intern. Med. (1999) 159:2161–2168.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, LAURITSEN K, TUNTURI-HIHNALA H et al.: Esomeprazole 20 mg maintains symptom control in endoscopy negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Alim. Pharmacol. Ther. (2001) 15:347–354.
   PubMed Web of Science ®Google Scholar
• MARTIN RM, DUNN NR, FREEMANTLE S, SHAKIR S: The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br. J. Clin. Pharmacol. (2000) 50:366–372.
   PubMed Web of Science ®Google Scholar
• KUIPERS EJ, LUNDELL L, KLINCKENBERG-KNOL EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with relux esophagitis treated with omeprazole after fundoplication. N Engl. J. Med. (1996) 334:1018–1022.
   PubMed Web of Science ®Google Scholar
• LUNDELL L, MEITTENEN P, MYRVOLD HE et al.: Lack of effect of acid suppression on gastric atrophy. Gastroenterology (1999) 117:319–326.
   PubMed Web of Science ®Google Scholar
• AXON ATR: Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease - an alternative hypothesis. Alim. Pharmacol. Ther. (2004) 19:253–262.
   PubMed Web of Science ®Google Scholar
• PEGHINI PL, KATZ PO, BRACY NA, CASTELL DO: Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am. J. GastroenteroL (1998) 93:763–767.
   PubMed Web of Science ®Google Scholar
• ARTS J, TACK J, GALMICHE JP: Endoscopic antireflux procedures. Gut (2004) 53:1207–1214.
   PubMed Web of Science ®Google Scholar
• KATZ PO, ANDERSON C, KHOURY R, CASTELL DO: Gastro-oesophageal reflux associated with nocturnal acid breakthrough on proton pump inhibitors. Alim. Pharmacol. Ther. (1998) 12:1231–1234.
   PubMed Web of Science ®Google Scholar
• OURS TM, FACKLER WK, RICHTER JE, VAEZI MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. (2003) 98: 545–550.
   PubMed Web of Science ®Google Scholar
• CASTELL DO: Nocturnal acid breakthrough in perspective: let's not throw the baby with the bathwater. Am. J. GastroenteroL (2003) 98:517–518.
   PubMed Web of Science ®Google Scholar
• MAES B, GEYPENS B, LUYPAERTS A, GHOOS Y, RUTGEERS P: ABT-229, a new motilin agonist, increases gastric emptying of solids in man. Gastroenterology (1996) 110:4.
   Google Scholar
• COWLES VE, NELLANS HN, SEIFERT TR et al.: Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs./ Pharmacol. Exp. Ther. (2000) 293:1106–1111.
   PubMed Web of Science ®Google Scholar
• VERLINDEN MH, MCCALLUM RW, SCHWARTZ S et al.: The macrolide gastrokinetic (GK) agent ABT-229 has an adverse effect on postprandial dyspeptic symptoms in patients with insulin dependant diabetes (DM). Gastroenterology (2000) 118:4\(suppl 2):A858.
   Google Scholar
• TALLEY NJ, VERLINDEN MH, SNAPE W et al.: Lack of anti-dyspeptic effects of the macrolide gastrokinetic (GK) agent ABT-229 in functional dyspepsia (FD) and idiopathic gastroparesis (IG). Gastroenterology (2000) 118\(Suppl. 2).
   Google Scholar
• VAN HERWAARDENMA, SAMSOM M, VAN NISPENCH, VERLINDEN M, SMOUT A: The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. Alim. Pharmacol. Thera)). (2000) 14:453–462.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, LEHMANN A, RIGDA R, DENT J, HOLLOWAY RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut (2002) 50:19–24.
   PubMed Web of Science ®Google Scholar
• VAN HERWAARDEN MA, SAMSOM M, RYDHOLM H, SMOUT AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Alim. Pharmacol. Ther. (2002) 16:1655–1662.
   PubMed Web of Science ®Google Scholar
• VAKIL N: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Alim. Pharmacol. Therap. (2004) 19:1041–1049.
   PubMed Web of Science ®Google Scholar
• COSSENTINO M, MAYDONOVITCH C, BELLE L, WONG R: The effect of baclofen on patients with gastroesophageal reflux disease: a prospective, randomized, double-blinded, placebo-controlled study. Gastroenterology (2003) 124:S1584.
   Web of Science ®Google Scholar
• CICCAGLIONE AF, MARZIO L: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut (2003) 52:464–470.
   PubMed Web of Science ®Google Scholar
• MEALY N: AZD-0865/AZD-3355/AZD-7371. Drugs of the Future. Drugs Future (2004) 29:509.
   Google Scholar
• NOBLE F, WANK SA, CRAWLEY JN et al.: International union of pharmacology XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. (1999) 51:4.
   Google Scholar
• LEE YM, BEINBORN M, MCBRIDE EW, LU M, KOLAKOWSKI LF, KOPIN AS: Thehuman brain cholecystokinin-B/gastrinreceptor. Cloning and characterization.BioL Chem. (1993) 268: 8164–8169.
   Google Scholar
• MORITA H, MUIRA N, HORT Y et al.: Effects of Z-360, a novel CCKb/gastrin (CCK2) receptor antagonist, on meal induced acid secretion and experimental ulcer models in dogs and rats. Gastroenterology (2001) 120\(Suppl. 1):A311.
   PubMedGoogle Scholar
• MUIRA N, YONETA T, UKAWA H et al.: Pharmacological profiles of Z-360, a novel CCKb/gastrin (CCK2) receptor antagonist with excellent oral potency. Gastroenterology (2001) 120\(Suppl. 1):A311.
   PubMedGoogle Scholar
• Pharma Japan (2001) 1741:April 09(5–6).
   Google Scholar
• SCARPIGNATO C, KISFALVI I, D'AMATO M, VARGA G: Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat. Alim. Pharmacol Thera)). (1996) 10: 411–419.
   Google Scholar
• D'AMATO M, WHORWELL PJ, THOMPSON DG et al.: The CCK-1 receptor antagonist dexloxiglumide does not increase the risk of gallstone formation. Am. J. Gastroenterol (2001) 96:9.
   Web of Science ®Google Scholar
• DE PONTI F: Pharmacology of serotonin: what a clinician should know. Gut (2004) 53:1520–1535.
   PubMed Web of Science ®Google Scholar
• PATEL S, BERRADA D, LEMBO A: Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin. Pharmacother. (2004) 5:2369–2379.
   PubMed Web of Science ®Google Scholar
• BUELBRING E, CREMA A: The release of5 hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J. Physiol (1959) 146:18–28.
   PubMed Web of Science ®Google Scholar
• KAHRILAS PJ, QUIGLEY EMM, CASTELL DO, SPECHLER SJ: The selective 5-HT4 receptor partial agonist HTF 919 reduces acid exposure in patients with gastroesophageal disease (GERD). Gastroenterology (1999) 116:A202.
   Google Scholar
• LEA R, WHORWELL PJ: Benefit-risk assessment of tegaserod in irritable bowel syndrome. Drug Safety (2004) 27:229–242.
   PubMed Web of Science ®Google Scholar
• FACKLER WK, OURS TM, VAEZI MF, RICHTER JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology (2002) 122:625–632.
   PubMed Web of Science ®Google Scholar
• BAROCELLI E, BALLABENI V, CHIAVARINI M, IMPICCIATORE M. R-alpha-methylhistamine-induced inhibition of gastric acid secretion in pylorus-ligated rats via central histamine H, receptors. Br. J. Pharmacol (1995) 115:1326–1330.
   PubMed Web of Science ®Google Scholar
• SOLDANI G, GARBARG M, INTORRE L et al.: Modulation of pentagastrin-induced histamine release by histamine H, receptors in the dog. Scand. Gastroenterol (1996) 31: 631–638.
   Google Scholar
• HOLSTEIN B, HOLMBERG A, FLORENTZSON M, HOLMBERG AA, ANDERSSON M, ANDERSSON K: A new potassium-competitive acid blocker - exhibits maximal gastric antisecretory effects from first dose. Gastroenterology (2004) 126\(Suppl. 2):A333.
   Google Scholar
• BRIVING C, SVENSSON K, MAXVALL I, ANDERSSON K: Mechanism of action of AZD0865, an H+,K+-ATPase selective, potassium-competitive acid blocker. Gastroenterology (2004) 126\(Suppl. 2):A333.
   Google Scholar
• CHUNG J-Y, LIM HS, BAE KS et al.: Evaluation of safety, tolerability, and pharmacokinetics/pharmacodynamics of a novel reversible proton pump inhibitor, YH1885. Am. Soc. Clin. Pharmacol Therap. (2001) 42:6–10.
   Google Scholar
• GALMICHE JP, BRULEY DES VARANNES S, DUCROTTE P et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Alim. Pharmacol. Ther. (2004) 19:655–662.
   PubMed Web of Science ®Google Scholar
• UCHIYAMA K, WAKATSUKI D, KAKINOKI B, TAKEUCHI Y, ARAKI T, MORINAKA Y: Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Meth. Find Exp. Clin. Pharmacol (1999) 21:115–122.
   PubMed Web of Science ®Google Scholar
• UCHIYAMA K, WAKATSUKI D, KAKINOKI B, TAKEUCHI Y, ARAKI T, MORINAKA Y: The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. Pharm. Pharmacol (1999) 51:457–464.
   PubMed Web of Science ®Google Scholar
• NIWA H, NAKAMURA T, MASAMUNE O et al.: Clinical usefulness of TU-199, a new anti-ulcer agent (tenatoprazole) in the treatement of peptic ulcer - a double randomized, comparative study with omeprazole. i>Rinsho Iyaku (1999) 15:465–497.
   Google Scholar
• KINBARA M: A pharmacokinetic study of TU-199 in aged healthy volunteers. fap. Pharmacol Therap. (1999) 27(Suppl. 5):53–60.
   Google Scholar
• Omeprazole/antacid powder suspension. Santarus: Acitrel, Rapinex powder for oral suspension. Drugs R D (2004) 5:234–235.
   PubMedGoogle Scholar
• GILLIAN' AD, WATSON SA, HEN WOOD M et al.: A Phase II study of G17DT in gastric carcinoma. Eur. j Surg. Oncol (2004) 30:536-543. Affiliation
   Google Scholar